Display options
Share it on

Diabetes Metab J. 2018 Jun;42(3):244-248. doi: 10.4093/dmj.2018.0002. Epub 2018 Apr 24.

Synthesis of a New Zinc-Mixed Ligand Complex and Evaluation of Its Antidiabetic Properties in High Fat Diet: Low Dose Streptozotocin Induced Diabetic Rats.

Diabetes & metabolism journal

Muruganantham Koothappan, Roshana Devi Vellai, Iyyam Pillai Subramanian, Sorimuthu Pillai Subramanian

Affiliations

  1. Department of Biochemistry, University of Madras, Guindy Campus, Chennai, India.
  2. PG and Research Department of Chemistry, Pachaiyappa's College, Chennai, India.
  3. Department of Biochemistry, University of Madras, Guindy Campus, Chennai, India. [email protected].

PMID: 29885106 PMCID: PMC6015968 DOI: 10.4093/dmj.2018.0002

Abstract

Due to the multifactorial and multisystemic nature of diabetes mellitus, it is often treated with a combination of therapeutic agents having different mode of action. Earlier, we have synthesized several organozinc complexes and evaluated their safety and antidiabetic properties in experimental type 2 diabetes mellitus (T2DM). More recently, we have synthesized a metformin-3-hydroxyflavone complex and studied its antidiabetic efficacy in experimental rats. In the present study, a new zinc-mixed ligand (metformin-3-hydroxyflavone) was synthesized, characterized by spectral studies and its antidiabetic properties was evaluated in HFD fed-low dose streptozotocin induced T2DM in rats. The hypoglycemic efficacy of the complex was evaluated through oral glucose tolerance test, homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index and by determining the status of important biochemical parameters. Oral administration of the complex at a concentration of 10 mg/kg body weight/rat/day for 30 days significantly improved the glucose homeostasis. The complex possesses significant antidiabetic properties relatively at a less concentration than metformin-3-hydroxyflavone complex in ameliorating hyperglycemia.

Copyright © 2018 Korean Diabetes Association.

Keywords: Diabetes mellitus, type 2; Hypoglycemic agents; Metformin; Rats; Zinc

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

  1. Adv Physiol Educ. 2012 Dec;36(4):275-83 - PubMed
  2. Chem Biol Interact. 2014 Aug 5;219:9-17 - PubMed
  3. Diabetes Care. 2009 Nov;32(11):1993-7 - PubMed
  4. Curr Top Med Chem. 2012;12(3):210-8 - PubMed
  5. Diabetes. 1980 Aug;29(8):665-7 - PubMed
  6. J Clin Diagn Res. 2015 Feb;9(2):BC05-9 - PubMed
  7. Eur J Pharmacol. 2012 Apr 5;680(1-3):122-9 - PubMed
  8. J Pharm Bioallied Sci. 2011 Oct;3(4):504-12 - PubMed
  9. JAMA. 1999 Jun 2;281(21):2005-12 - PubMed
  10. Biochem Res Int. 2015;2015:350829 - PubMed
  11. Pharmacol Res. 2005 Oct;52(4):313-20 - PubMed

Publication Types